Is It Normal to Gain Weight on Wegovy?

What the STEP 1 trial actually showed, and what it didn't

The foundational evidence for semaglutide 2.4mg comes from the STEP 1 trial, published in the New England Journal of Medicine. Over 68 weeks, participants using semaglutide alongside lifestyle changes lost an average of around 15% of their body weight compared with roughly 2.5% for those on placebo. That average, though, masks a wide spread of individual responses. Some participants lost considerably more; a smaller number lost very little. The trial data was never a promise that every person would follow the same curve downward.

Critically, STEP 1 measured weight at regular intervals, not as a single unbroken slide. Fluctuations between visits were common. Water retention, digestive slowdown from gastric-emptying effects, and the timing of meals relative to a weigh-in can all shift the reading by a kilogram or two without any change in actual fat mass. So if your weight has ticked up over a single week or two, particularly early in treatment or just after a dose step, the trial design itself would predict that as noise rather than signal.

The Wegovy overview on this site covers the trial results in more detail if you want the broader picture before a consultation.

Why weight sometimes rises during the titration phase

A question our prescribers hear most weeks is some version of: "I've been on Wegovy for a month and I've actually put on weight, is it broken?" The honest answer is that it very often isn't. The early dose steps (0.25mg, then 0.5mg) are tolerated doses designed to let your body adjust, not therapeutic doses designed to produce significant weight loss. At those levels, appetite suppression is mild and the full mechanism has not yet reached its working intensity. Meanwhile, nausea can reduce activity levels, constipation can add retained weight on the scales, and some people eat slightly more carbohydrate-rich foods to manage nausea, all factors that can tip the number upward.

The nausea side effects that often accompany early treatment have their own dynamics worth understanding, because they directly affect how people eat in the first few weeks. Once the maintenance dose is established and GI symptoms settle, the weight trajectory typically shifts. If it doesn't, that is a legitimate clinical concern, not something to sit with in silence.

For context on what dose levels actually look like in practice, the explainer on lower Wegovy doses covers why some people manage at less than the standard schedule.

Weight gain after stopping Wegovy, why this happens and what to expect

The most consistent finding in the post-trial literature is that a significant portion of lost weight returns once semaglutide is discontinued. A follow-up to the STEP 1 trial found that a year after stopping treatment, participants had regained much of the weight they had lost during the active phase. This is not a failure of willpower. Obesity is a chronic condition driven partly by hormonal and metabolic factors; semaglutide addresses those factors while it is being taken, and those factors reassert themselves when it is not.

NHS guidance on semaglutide is clear that treatment is intended to be taken alongside sustained lifestyle changes, and that stopping abruptly (or without a plan) is associated with weight returning. If you are concerned about what happens to your weight after you stop, or you are wondering whether to continue, that is a direct prescriber question.

There is a fuller discussion of what typically happens on the weight regain after Wegovy page for anyone thinking about that transition.

When a weight increase on Wegovy genuinely warrants clinical attention

Short-term fluctuation is one thing. Sustained, unexplained weight gain after several months on a stable maintenance dose is another. Possible clinical explanations include: the medicine not absorbing correctly (oral contraceptive use can interact with semaglutide's gastric-emptying effects, for instance), an unrelated medical change such as thyroid function shifting, or the dose not being appropriate for this individual at this point. None of those are situations to guess your way through.

The clinical question of whether Wegovy can directly cause weight gain is addressed in more depth separately, including the specific mechanisms that might produce a genuine rather than apparent increase. Similarly, the broader page on weight gain during Wegovy treatment covers the scenarios where the medicine may simply not be working as expected for someone's biology.

On the cost side, if you are wondering whether treatment is sustainable for the long term, the Wegovy cost page sets out what private treatment typically involves in the UK.

If anything in your treatment feels off (whether the scales are moving the wrong way or you have other concerns) speaking to a prescriber is always the right step. At nume, our prescribers review every repeat order before it is dispensed. Speak to our prescribers through a free consultation and they can look at your full picture, not just the number on the scales.